A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors
This study is testing an experimental medication called IKS014 for adults with advanced cancers, such as breast or stomach cancer. The goal is to find the safest and most effective dose of this new drug.
You might be able to join if you have certain advanced solid tumors that test positive or low for the HER2 protein, and your general health meets specific blood test requirements. However, people with certain past lung conditions or current eye issues cannot participate.
Participants will receive the study medication while doctors closely monitor their safety, side effects, and how the drug affects their cancer. You will have regular health check-ups and blood tests throughout the process.
This study is currently recruiting participants and takes place at medical centers in Newport Beach, California; Boston, Massachusetts; and Nashville, Tennessee.
- 1Testing a new drug called IKS014 for advanced cancers
- 2Currently recruiting patients at select US locations
- 3Involves careful health monitoring and safety checks
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.